Insiders Aren’t Buying Pfizer Stock, and That Could Help
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
When To Harvest Losses In Dividend ETFs offers timing guidance for realizing losses to optimize your tax outcomes.
10,702 articlesPfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Value stocks are resurging as inflation cools and markets favor durable cash flow. This piece examines why Vanguard M...
Oil markets stabilize as July opens, setting up a three-stock energy play. Exxon, Chevron, and ConocoPhillips offer d...
When a large investor opens million position in an industrial REIT, it signals confidence in long-term cash flow and ...
Two powerhouses sit on opposite ends of the energy spectrum. This guide compares Brookfield Renewable and Enterprise ...
Two oil giants enter 2026 with contrasting plays: Occidental Petroleum pares back, focusing on the Permian, while Exx...
As markets enter the midyear phase of 2026, three proven compounders highlight why patient investing still works. App...
Looking ahead to the second half of 2026, investors debate whether Energy Transfer or Occidental Petroleum offers the...
Oil jumps amid Middle East tensions, yet midstream dividends from EPD and its peers remain steady. The sector’s fee-b...
Nuclear energy stocks are poised for renewed interest in 2026 thanks to reliability, carbon-free power, and policy ta...
Investors face a pivotal choice in 2026: a dependable defense powerhouse or a cyclical recovery in commercial aviatio...
Two defense giants, two paths to growth. This guide breaks down Lockheed Martin and RTX, outlining which offers more ...